Low-cost Haemophilia A treatment deal unlocks world of opportunity for ProFactor Pharma
Low-cost Haemophilia A treatment deal unlocks world of opportunity for ProFactor Pharma New agreement with Bio Farma opens estimated $1.36bn addressable Asian market A new patented process to make low-cost treatment for Haemophilia A, developed by Scottish biotechnology company ProFactor Pharma Ltd (PFP),...
Source: pharmiweb.com